Updated ASTRO Pancreatic Guidelines: Key Takeaways for Oncology Nurses

Epidemiologic models project that pancreatic cancer will become the second leading cause of cancer-related mortality in the United States by 2030. In 2026, an estimated 67,500 US adults will receive a diagnosis of pancreatic cancer, with 52,700 deaths and a 5-year survival rate of 13% across all stages. Because fewer than 20% of patients present with surgically resectable disease at initial diagnosis, multidisciplinary management integrating systemic chemotherapy, radiation therapy, and surgical intervention is essential to optimize patient outcomes.

To address evolving clinical evidence, the American Society for Radiation Oncology (ASTRO) published an updated clinical practice guideline on radiation therapy for adult pancreatic cancer in Practical Radiation Oncology, replacing its 2019 recommendations. The guideline was developed in collaboration with the American Society of Clinical Oncology, the European Society for Radiotherapy and Oncology, and the Society of Surgical Oncology.

In an interview with Oncology Nursing News, Michael D. Chuong, MD, vice chair of the ASTRO guideline task force and vice chair and medical director of radiation oncology at the Baptist Health Herbert Wertheim Cancer Institute, highlighted nursing's pivotal role: "Pancreatic cancer patients face a lot of challenges in terms of not only treatment-related toxicities but also just being able to be navigated through the treatment process."

Strengthened Evidence Base Across Settings

The updated guideline establishes stronger recommendations across resectable, borderline resectable, locally advanced, recurrent, and metastatic disease settings.

"The real reason behind the update for the guideline is really the emergence of a few key aspects," Chuong explained in the interview. "One is the publication of multiple practice-informing prospective clinical trials that further support the routine use of radiation. ... Also, since the prior guideline was published, there have been advances in technological capabilities of radiation to deliver higher doses as well as to deliver more comprehensive radiation in terms of targeting and that has achieved further improved outcomes.”

For resectable disease, preoperative chemoradiation is conditionally recommended to reduce local recurrence risk. Chuong noted that prospective trials support this approach: "There are emerging prospective data, in particular there are two trials called the PREOPANC [NCT01591707] and then the PREOPANC-2 [NCT02692482] trials that demonstrated that the use of pre-operative chemoradiation is a reasonable approach. ... Nursing staff can really be critical in helping guide patients by helping to educate patients that radiation therapy has been demonstrated to be safe and feasible in that setting."

For borderline resectable disease, preoperative radiation or chemoradiation is recommended to increase margin-negative resections.

In the postoperative setting, recommendations draw from the randomized phase 3 RTOG 0848 trial (NCT00898261). Postoperative chemoradiation yielded a statistically significant overall survival benefit in patients with pathologically uninvolved lymph nodes (pN0).

"While postoperative chemo radiation did not demonstrate an overall survival benefit after surgery in addition to chemotherapy for all patients, there was a significant overall survival advantage for patients who had node-negative disease," Chuong stated. "So being aware of patients' nodal status really is important to help guide patients based on these data.” He added that node-positive (pN1) patients may also derive individualized benefit following multidisciplinary discussion.

Precision Technologies and Toxicity Management

Modern radiation therapy utilizes intensity-modulated radiation therapy, daily volumetric image guidance, respiratory motion assessment, and adaptive radiation therapy. Highlighting patient coaching, Chuong explained: "Nursing education to patients is really critical, especially when we are offering patients advanced motion management strategy. ... Educating patients on the importance of this and also how to most effectively do this really is a key aspect of how nurses can be integrated into the care of these patients.”

Expanding Palliative Interventions

The guideline expands recommendations for radiation therapy in oligometastatic, oligoprogressive, and symptomatic disease settings. "There's this emerging area of indications including for metastatic patients and those who are symptomatic—for example, who have pain," Chuong observed. "There are now prospective clinical trials showing that just one treatment of high-dose radiation can significantly decrease pain. ... Identifying those patients who may particularly benefit from something like that really is critical.”

Key Takeaways for Oncology Nurses

• Recognize Expanded Indications: Radiation indications now encompass metastatic disease, locoregional recurrence, and single-fraction high-dose pain relief.
• Verify Surgical Nodal Status: Check pathology reports for pN0 status to identify patients benefiting from postoperative chemoradiation.
• Guide Preoperative Expectations: Educate patients that preoperative chemoradiation is safe and feasible.
• Coach Motion Management: Instruct patients on breath-hold cycles during treatment to ensure precise radiation delivery and protect organs at risk.
• Promote Prophylactic Care: Initiate early supportive medications, including prophylactic antiemetics, to minimize toxicities and preserve adherence.
• Advocate for Palliation: Screen patients for severe pain, bleeding, or obstruction, advocating for prompt palliative radiation consultations.

Quality of Life and Long-Term Survival

Advancements in dose escalation and target coverage have improved clinical outcomes. "Understanding that the emerging data with more comprehensive and ablative radiation has resulted in significantly improved outcomes and long-term survival is no longer a far-fetched dream," Chuong concluded. "Maintaining high quality of life is a very common benefit of these modern techniques and a main reason why we included such a strong recommendation for them in the guideline.”

Reference

1. American Society for Radiation Oncology. ASTRO updates guideline on radiation therapy for pancreatic cancer. News release. Published August 13, 2026. Accessed September 9, 2026. https://www.astro.org